Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study

被引:24
|
作者
Worm, Signe W. [1 ]
Sabin, Caroline A. [2 ]
Reiss, Peter [3 ]
El-Sadr, Wafaa [4 ]
Monforte, Antonella D'Arminio [5 ]
Pradier, Christian [6 ]
Thiebaut, Rodolphe [7 ]
Law, Matthew [8 ]
Rickenbach, Martin [9 ]
De Wit, Stephane [10 ]
Lundgren, Jens D. [1 ]
Friis-Moller, Nina [1 ]
机构
[1] Univ Copenhagen, Copenhagen HIV Programme, Copenhagen, Denmark
[2] Royal Free & Univ Coll, London, England
[3] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[4] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Div Infect Dis, New York, NY 10032 USA
[5] Univ Milan, Milan, Italy
[6] Hop Archet J, Nice, France
[7] Univ Victor Segalen, Bordeaux, France
[8] Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[9] Univ Lausanne Hosp, Lausanne, Switzerland
[10] Univ Hosp St Pierre, Brussels, Belgium
关键词
REVERSE-TRANSCRIPTASE INHIBITORS; CORONARY-HEART-DISEASE; ANTIRETROVIRAL THERAPY; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; RISK-FACTORS; PREVALENCE; MORTALITY; HEALTH; COHORT;
D O I
10.2337/dc08-1394
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - It is much debated whether the metabolic syndrome contributes additional information over and above that provided by the individual components of the syndrome alone Among HIV-infected individuals, we investigated whether any particular combinations of the components included in the definition Of the metabolic syndrome are associated with a higher risk of cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS - We followed 33,347 HIV-infected individuals in a prospective observational study. The effect of combinations of components of the metabolic syndrome (low HDL Cholesterol, high triglycerides, high BMI, hypertension, and diabetes) on the risk of CVD was assessed by Poisson regression incorporating interactions between each component pair and adjusting for age, sex, family history of CVD, smoking status, calendar year, and exposure to antiretroviral therapy. We reduced the risk of type 1 errors by randomly Splitting the data set for training (70% of sample) and validation (remaining 30%). RESULTS - in the training data set, 671 patients experienced a CVD event over 110,652 person-years. Unadjusted, the presence of metabolic syndrome at study enrollment (>= 3 of the factors) was associated with a 2.89 higher risk of CVD (95% CI 2.34-3.59; P = 0.0001) compared with individuals without the metabolic syndrome. After adjustment for the individual components, the metabolic syndrome as an entity no longer predicted the risk of CVD (adjusted relative risk 0.85; 95% CI 0.61-1.17; P = 0.32). No significant positive interactions were found among the components of the metabolic syndrome. CONCLUSIONS - The presence of the metabolic syndrome in HIV-infected individuals did not appear to increase the CVD risk over and above that conferred by the components of the syndrome separately,
引用
收藏
页码:474 / 480
页数:7
相关论文
共 18 条
  • [1] Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA
    Mills, A. M.
    Schulman, K. L.
    Fusco, J. S.
    Brunet, L.
    Hsu, R.
    Beyer, A.
    Prajapati, G.
    Mounzer, K.
    Fusco, G. P.
    [J]. HIV MEDICINE, 2020, 21 (05) : 299 - 308
  • [2] Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study
    Friis-Moller, Nina
    Thiebaut, Rodolphe
    Reiss, Peter
    Weber, Rainer
    Monforte, Antonella D'Arminio
    De Wit, Stephane
    El-Sadr, Wafaa
    Fontas, Eric
    Worm, Signe
    Kirk, Ole
    Phillips, Andrew
    Sabin, Caroline A.
    Lundgren, Jens D.
    Law, Matthew G.
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 (05): : 491 - 501
  • [3] Incidence and risk factors for new-onset diabetes, in HIV-infected patients -: The data collection on adverse events of Anti-HIV drugs (D:A:D) study
    De Wit, Stephane
    Sabin, Caroline A.
    Weber, Rainer
    Worm, Signe Westring
    Reiss, Peter
    Cazanave, Charles
    El-Sadr, Wafaa
    Monforte, Antonella D'Arminio
    Fontas, Eric
    Law, Matthew G.
    Friis-Moller, Nina
    Phillips, Andrew
    [J]. DIABETES CARE, 2008, 31 (06) : 1224 - 1229
  • [4] Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study The Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group
    Worm, S. W.
    Friis-Moller, N.
    Sabin, C. A.
    Sjol, A.
    Lundgren, J. D.
    Salbol-Brandt, R.
    Rickenbach, M.
    Pezzotti, P.
    Krum, E.
    Gras, L.
    Balestre, E.
    Sundstroem, A.
    Delforge, M.
    Fontas, E.
    Torres, F.
    Petoumenos, K.
    Kjaer, J.
    Collins, S.
    Storpher, S.
    Pearce, G.
    Rode, R.
    Weller, I.
    [J]. AIDS, 2010, 24 (10) : 1537 - 1548
  • [5] Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study
    Hatleberg, C. I.
    Ryom, L.
    Monforte, A. d'Arminio
    Fontas, E.
    Reiss, P.
    Kirk, O.
    El-Sadr, W.
    Phillips, A.
    de Wit, S.
    Dabis, F.
    Weber, R.
    Law, M.
    Lundgren, J. D.
    Sabin, C.
    [J]. HIV MEDICINE, 2018, 19 (09) : 605 - 618
  • [6] The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV
    Anikpo, Ifedioranma
    Agovi, Afiba Manza-A.
    Cvitanovich, Matthew J.
    Lonergan, Frank
    Johnson, Marc
    Ojha, Rohit P.
    [J]. HIV MEDICINE, 2021, 22 (10) : 936 - 943
  • [7] An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study
    Friis-Moller, Nina
    Ryom, Lene
    Smith, Colette
    Weber, Rainer
    Reiss, Peter
    Dabis, F.
    De Wit, Stephane
    Monforte, Antonella D'Arminio
    Kirk, Ole
    Fontas, Eric
    Sabin, Caroline
    Phillips, Andrew
    Lundgren, Jens
    Law, Matthew
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2016, 23 (02) : 214 - 223
  • [8] An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons; the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) Study
    Friis-Moller, N.
    Ryom, L.
    Smith, C.
    Weber, R.
    Reiss, P.
    Dabis, F.
    De Wit, S.
    Monforte, A. d'Arminio
    Kirk, O.
    Fontas, E.
    Sabin, C.
    Phillips, A.
    Lundgren, J. D.
    Law, M.
    [J]. ANTIVIRAL THERAPY, 2013, 18 : A23 - A24
  • [9] Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study
    Petoumenos, Kathy
    Worm, Signe W.
    Fontas, Eric
    Weber, Rainer
    De Wit, Stephane
    Bruyand, Mathias
    Reiss, Peter
    El-Sadr, Wafaa
    Monforte, Antonella D'Arminio
    Friis-Moller, Nina
    Lundgren, Jens D.
    Law, Matthew G.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15
  • [10] Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)
    Worm, Signe W.
    De Wit, Stephane
    Weber, Rainer
    Sabin, Caroline A.
    Reiss, Peter
    El-Sadr, Wafaa
    Monforte, Antonella D'Arminio
    Kirk, Ole
    Fontas, Eric
    Dabis, Francois
    Law, Matthew G.
    Lundgren, Jens D.
    Friis-Moller, Nina
    [J]. CIRCULATION, 2009, 119 (06) : 805 - U75